Multiple Sclerosis Clinical Trial
Official title:
Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
Primary fatigue represents a major cause of disability in patients with multiple sclerosis (MS), being reported in about 90% of cases. Fatigue interferes with everyday functioning but, unfortunately, little is known about its mechanisms. The investigators propose a characteristic eye movement abnormality (internuclear ophthalmoparesis, INO), commonly encountered in MS, as a simple model for primary motor fatigue. The investigators described worsening of ocular performance in MS patients with INO following visual tasks (ocular motor fatigue), which is likely due to decreased neural conduction along brain pathways injured by MS. This mechanism could represent a major component of MS-related primary motor fatigue. Relevant to Veterans' care, INO is a significant cause of visual disability, especially when complicated by ocular fatigue, and limits daily activities such as reading and driving. The investigators propose a medical treatment to improve ocular performance/fatigue in INO, which can reduce visual disability and improve quality of life in Veterans with MS.
This project focuses on fatigue, an extremely common yet poorly understood complaint in
patients affected by multiple sclerosis (MS). Primary fatigue, that is fatigue not secondary
to other MS-associated symptoms (e.g., sleep disorder or depression), is a distinct clinical
entity and a cause of severe disability in most patients. As fatigue limits everyday
activities and interferes with exercise-based rehabilitation, understanding its mechanisms is
crucial to improving function and quality of life of Veterans with MS. Primary fatigue is
divided in two broad categories, mental (cognitive) and physical (motor) fatigue, the latter
being the focus of this proposal. Evidence suggests that primary motor fatigue originates
within the central nervous system (CNS) but, although several factors have been invoked
(e.g., demyelination, axonal loss, inflammation), a neurophysiological model to explain its
underlying mechanisms is still lacking.
First, with this project, the investigators propose a characteristic eye movement
abnormality, internuclear ophthalmoparesis (INO), as a simple and accessible model for
primary motor fatigue in MS. INO is a disorder of binocular coordination (conjugacy), in
which fast eye movements (saccades) of the adducting eye (i.e., the eye moving towards the
nose) are slow during horizontal gaze shifts, due to demyelination of a specific CNS pathway
(the medial longitudinal fasciculus, MLF). Preliminary results in a small MS group of
patients show that patients with INO exhibit changes in ocular conjugacy (i.e., ocular motor
fatigue) during a 10-minute saccadic fatigue test, but normal subjects do not. The
investigators hypothesize that ocular motor fatigue is representative of a major component of
primary motor fatigue in MS, as it likely reflects deterioration of neural conduction
fidelity along the demyelinated MLF axons. The investigators aim at showing that ocular motor
fatigue occurs in a larger MS population with INO by measuring changes of binocular conjugacy
on eye movement recordings using two main measures: 1) abducting/adducting eye ratio for
saccadic peak velocity (pulse size ratio); 2) time difference in occurrence of peak
acceleration in the adducting vs. the abducting eye (pulse time delay), during the 10-minute
fatigue test. The investigators will determine whether ocular motor fatigue is associated
with symptomatic subjective fatigue as assessed with standard fatigue questionnaires. Second,
The investigators intend to test efficacy of dalfampridine, a potassium channel blocker that
enhances neural conduction along demyelinated axons, in MS patients with INO with or without
associated ocular motor fatigue. Visual dysfunction in MS patients with INO is a major cause
of disability as they are severely limited in daily activities such as driving and can suffer
further disability when developing ocular motor fatigue during a sustained visual task (e.g.,
reading). However, no medical therapy is available for INO/ocular motor fatigue. Preliminary
results document improved binocular conjugacy in three MS patients taking dalfampridine for
gait impairment (the FDA-approved indication for this medication). These data also showed
improvement of ocular motor fatigue after dalfampridine in one patient. The investigators
hypothesize that dalfampridine improves visual performance in MS patients with INO and
counteracts ocular motor fatigue and, in turn, diminishes visual disability and improves
quality of life. Thus, the investigators will conduct a randomized, placebo-controlled,
double-blind, crossover trial of dalfampridine (10mg twice a day) of 10 weeks duration.
Before and after treatment, the investigators will assess for changes in binocular conjugacy
by eye movement measures as above, as well as changes in clinical measures, such as reading
acuity and speed, saccades performance, gait performance, symptomatic fatigue, visual
disability and quality of life. the investigators will determine whether improvement of
visual performance has positive effects on overall disability and quality of life of MS
patients with INO. The investigators will also determine whether there is an association
between response of eye movement and gait performances to dalfampridine.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|